References of "Francotte, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNew trends in the design of drugs against Alzheimer's disease
Francotte, Pierre ULg; De Tullio, Pascal ULg; Fraikin, Pierre ULg et al

in Frontiers in Medicinal Chemistry (2006), 3

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailIn Search of Novel Ampa Potentiators
Francotte, Pierre ULg; De Tullio, Pascal ULg; Fraikin, Pierre ULg et al

in Recent Patents on CNS Drug Discovery (2006), 1(3), 239-46

Glutamate is the major excitatory neurotransmitter in the brain. Amongst ionotropic receptors responding to glutamate, the AMPA subtype has been considered as essential for the fast excitatory ... [more ▼]

Glutamate is the major excitatory neurotransmitter in the brain. Amongst ionotropic receptors responding to glutamate, the AMPA subtype has been considered as essential for the fast excitatory neurotransmission in the central nervous system and the expression and maintenance of long-term potentiation. As glutamate is known to be involved in many neurological and psychiatric disorders, AMPA receptors seem to represent interesting targets to develop therapeutic drugs. Hence, the enhancement of AMPA signals is an approach currently investigated for the management of Alzheimer's disease, schizophrenia or mood disorders. In particular, many efforts are being conducted in the development of AMPA positive allosteric modulators ("potentiators"), which alter the rate of receptor desensitization. The major chemical families developed as AMPA potentiators are aniracetam derivatives, cyclothiazide derivatives and biarylpropylsulfonamides derivatives. [less ▲]

Detailed reference viewed: 47 (21 ULg)
Full Text
Peer Reviewed
See detailNew trends in the development of positive allosteric modulators of AMPA receptors
Graindorge, E.; Francotte, Pierre ULg; Boverie, S. et al

in Current Medicinal Chemistry - Central Nervous System Agents (2004), 4

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailNew trends in the design of drugs against Alzheimer's disease
Francotte, Pierre ULg; Graindorge, Emmanuel; Boverie, Stéphane et al

in Current Medicinal Chemistry (2004), 11(13), 1757-1778

First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a ... [more ▼]

First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem. AD is currently treated by symptomatic drugs, the acetylcholinesterase inhibitors. based on the cholinergic hypothesis (1976). During the past decade, advances in neurobiology have conducted to the identification of new targets. Although some of these innovative approaches tend to delay onset of AD, others are still symptomatic. In this review, we present an overview of the several strategies and new classes of compounds against AD. [less ▲]

Detailed reference viewed: 36 (12 ULg)